Erudio Healtherudio.com
Drug
Niraparib trials: what clinicians said in public
HCP commentary reports on 3 clinical trials studying niraparib: MiST, RADIAN and TOPACIO. Each covers what clinicians said in public about one trial, on podcasts, videos and posts, every statement linked to its source. Below them, 11 more trials with public commentary and no report yet.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| TOPACIO NCT02657889 · Tesaro, Inc. | advanced triple-negative breast cancer or recurrent ovarian cancer | Phase 1/Phase 2 | 183 | 30 | Standard | Nov 15, 2026 | Preview |
| MiST NCT03654833 · University of Leicester | relapsed malignant mesothelioma | Phase 2 | 227 | 35 | Focused | Nov 1, 2026 | Preview |
| RADIAN NCT05784012 · Grupo Español de Tratamiento de Tumores de Cabeza y Cuello | locally advanced head and neck squamous cell carcinoma | Phase 1/Phase 2 | 19 | 8 | Focused | Oct 29, 2026 | Preview |
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| RUBY NCT03981796 · Tesaro, Inc. DeepView → | primary advanced or recurrent endometrial cancer | Phase 3 | Deep | View | |||
| GALAHAD NCT02854436 · Janssen Research & Development, LLC DeepView → | metastatic castration-resistant prostate cancer with DNA-repair gene defects | Phase 2 | Deep | View | |||
| GUNS NCT04812366 · University of British Columbia DeepView → | high-risk localized prostate cancer | Phase 2 | Deep | View | |||
| ZEST NCT04915755 · GlaxoSmithKline DeepView → | HER2-negative BRCA-mutated or triple-negative breast cancer, molecular disease | Phase 3 | Deep | View | |||
| MORPHEUS-UC NCT03869190 · Hoffmann-La Roche StandardView → | urothelial carcinoma | Phase 1/Phase 2 | Standard | View | |||
| C3NIRA NCT04592237 · M.D. Anderson Cancer Center FocusedView → | aggressive variant metastatic prostate cancer | Phase 2 | Focused | View | |||
| ZEAL-1L NCT04475939 · GlaxoSmithKline FocusedView → | advanced or metastatic non-small cell lung cancer | Phase 3 | Focused | View | |||
| ASCLEPIuS NCT04194554 · University of Michigan Rogel Cancer Center FocusedView → | high-risk and node-positive prostate cancer | Phase 1/Phase 2 | Focused | View | |||
| MAGNITUDE NCT03748641 · Janssen Research & Development, LLC FocusedView → | metastatic castration-resistant prostate cancer | Phase 3 | Focused | View | |||
| NADIR NCT04037254 · NRG Oncology FocusedView → | high-risk prostate cancer | Phase 1/Phase 2 | Focused | View | |||
| PAVO NCT05169437 · Tempus AI FocusedView → | locally advanced or metastatic PALB2-mutated solid tumors | Phase 2 | Focused | View | |||